Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma
- PMID: 31254927
- DOI: 10.1016/j.cyto.2019.154762
Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma
Abstract
Pancreatic cancer is an aggressive disease with a poor prognosis for which current standard chemotherapeutic treatments offer little survival benefit. Receptor tyrosine kinases (RTK)s have garnered interest as therapeutic targets to augment or replace standard chemotherapeutic treatments because of their ability to promote cell growth, migration, and survival in various cancers. Met and Ron, which are homologous RTKs activated by the ligands hepatocyte growth factor (HGF) and macrophage stimulating protein (MSP), respectively, are over-activated and display synergistic malignant effects in several cancers. Despite the homology between Met and Ron, studies that have directly compared the functional outcomes of these systems in any context are limited. To address this, we sought to determine if the HGF/Met and MSP/Ron systems produce overlapping or divergent contributions towards a malignant phenotype by performing a characterization of MSP and HGF driven signaling, behavioral, and transcriptomic responses in a primary pancreatic adenocarcinoma (PAAD) cell line in vitro. The impact of dual Met and Ron expression signatures on the overall survival of PAAD patients was also assessed. We found HGF and MSP both encouraged PAAD cell migration, but only HGF increased proliferation. RNA sequencing revealed that the transcriptomic effects of MSP mimicked a narrow subset of the responses induced by HGF. Analysis of clinical data indicated that the strong prognostic value of Met expression in primary PAAD does not appear to be modulated by Ron expression. The relatively reduced magnitude of MSP-dependent effects on primary PAAD cells are consistent with the limited prognostic value of Ron expression in this cancer when compared to Met. Although HGF and MSP produced a differing breadth of responses in vitro, overlapping pro-cancer signaling, behavioral, and transcriptional effects still point to a potential role for the MSP/Ron system in pancreatic cancer.
Keywords: Cancer; HGF; MSP; Met; Pancreatic; Ron.
Published by Elsevier Ltd.
Similar articles
-
Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.Anticancer Drugs. 2016 Sep;27(8):766-79. doi: 10.1097/CAD.0000000000000390. Anticancer Drugs. 2016. PMID: 27314431 Free PMC article.
-
Hepatocyte growth factor and macrophage-stimulating protein are upregulated during excisional wound repair in rats.Cell Tissue Res. 2001 Nov;306(2):239-50. doi: 10.1007/s004410100443. Cell Tissue Res. 2001. PMID: 11702235
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.Cancer Biol Ther. 2011 Jul 1;12(1):9-46. doi: 10.4161/cbt.12.1.15747. Epub 2011 Jul 1. Cancer Biol Ther. 2011. PMID: 21543897 Free PMC article.
-
The scatter factor signaling pathways as therapeutic associated target in cancer treatment.Curr Med Chem. 2010;17(25):2699-712. doi: 10.2174/092986710791859261. Curr Med Chem. 2010. PMID: 20586722 Review.
-
Hepatocyte Growth Factor and Macrophage-stimulating Protein "Hinge" Analogs to Treat Pancreatic Cancer.Curr Cancer Drug Targets. 2019;19(10):782-795. doi: 10.2174/1568009619666190326130008. Curr Cancer Drug Targets. 2019. PMID: 30914029 Review.
Cited by
-
Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.Front Oncol. 2019 Dec 5;9:1377. doi: 10.3389/fonc.2019.01377. eCollection 2019. Front Oncol. 2019. PMID: 31867280 Free PMC article.
-
Feature screening for survival trait with application to TCGA high-dimensional genomic data.PeerJ. 2022 Mar 10;10:e13098. doi: 10.7717/peerj.13098. eCollection 2022. PeerJ. 2022. PMID: 35291482 Free PMC article.
-
Phospholipid Phosphatase 4 as a Driver of Malignant Glioma and Pancreatic Adenocarcinoma.Front Oncol. 2021 Nov 30;11:790676. doi: 10.3389/fonc.2021.790676. eCollection 2021. Front Oncol. 2021. PMID: 34917513 Free PMC article.
-
The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies.Cancers (Basel). 2022 Apr 18;14(8):2037. doi: 10.3390/cancers14082037. Cancers (Basel). 2022. PMID: 35454943 Free PMC article. Review.
-
Engineered biomaterial strategies for controlling growth factors in tissue engineering.Drug Deliv. 2020 Dec;27(1):1438-1451. doi: 10.1080/10717544.2020.1831104. Drug Deliv. 2020. PMID: 33100031 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous